Vericel (VCEL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Vericel

NasdaqGM•Healthcare•Biotechnology

$40.02-0.01(<0.01%)Market closed

Market Cap

$2.04B

P/E

84.4x

P/S

6.7x

P/B

5.5x

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

How this company scores

GoodMetricSide Score: 77/100

Strongest: Growth (23/25); weakest: Cash & Earnings Quality (17/25).

Profitability17/25

Growth23/25

Balance Sheet & Red Flags20/25

Cash & Earnings Quality17/25

Strengths

Growing revenueRising earningsLow leverageProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 84.4x5y range 72.3x – 10511.4x

Currently below its 11-quarter median.

P/S · 6.7x5y range 5.3x – 14.6x

Currently near its 20-quarter median.

P/B · 5.5x5y range 4.4x – 14.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg 2.5x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $2.04B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $306.30M
Q. Revenue: $77.46M
TTM EBITDA: $31.15M
TTM Op. Income: $18.23M
Q. Op. Income: $434,000
TTM Net Income: $24.22M
Q. Net Income: $2.21M
EPS: $0.04
Shares Out.: $51.08M

$306.30M in TTM revenue grew 23.0% YoY, reaching $77.46M last quarter. TTM EBITDA of $31.15M and TTM operating income of $18.23M show growth is flowing through to the bottom line. TTM net income of $24.22M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 72.8%
EBITDA Margin: 5.2%
Op. Margin: 0.6%
Net Margin: 2.8%

Op. margin of 0.6% is up 3.8% YoY — cost efficiency is improving. Net margin at 2.8% and gross margin of 72.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 117% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 84.4x
P/S Ratio: 6.7x
P/B Ratio: 5.5x

At 84.4x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 6.7x and P/B of 5.5x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 72% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $502.87M
Cash: $125.36M
Long-Term Debt: $480,000
Book Value: $370.04M
D/E Ratio: 0.0
Debt/EBITDA: 0.1

With $502.87M in assets and $480,000 in long-term debt, D/E is 0.0and book value is $370.04M — a conservative capital structure with a cushion to weather downturns. Across the last 7 quarters, debt/equity has fallen for 6 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $16.19M
TTM Free Cash Flow: $61.66M
FCF Margin: 20.1%
FCF / Net Income: 2.5

TTM FCF of $61.66M on $16.19M in operating cash flow. The FCF / Net Income ratio of 2.5x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.